Amgen Buys Dark Blue In $840 Million Bet On New Leukemia Drugs

Benzinga01-08

On Tuesday, Amgen Inc. (NASDAQ:AMGN) acquired Dark Blue Therapeutics, a discovery and development biotech company focused on precision oncology medicines. The acquisition values Dark Blue Therapeutics...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2601383721?lang=en_US&edition=fundamental","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/01/07/Amgen-Photo-by-JHVEPhoto-via-Shutterstoc.jpeg?optimize=medium&dpr=2&auto=webp&width=630","is_english":true,"pubTime":"2026-01-08 02:45","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2601383721","market":"us","top_or_hot":-1,"title":"Amgen Buys Dark Blue In $840 Million Bet On New Leukemia Drugs","media":"Benzinga","content":"<div>\n<p>On Tuesday, Amgen Inc. (NASDAQ:AMGN) acquired Dark Blue Therapeutics, a discovery and development biotech company focused on precision oncology medicines.\nThe acquisition values Dark Blue Therapeutics...</p>\n\n<a href=\"https://www.benzinga.com/m-a/26/01/49764675/amgen-buys-dark-blue-in-840-million-bet-on-new-leukemia-drugs\">Source Link</a>\n\n</div>\n","source":"benzinga_hot_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Amgen Buys Dark Blue In $840 Million Bet On New Leukemia Drugs</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAmgen Buys Dark Blue In $840 Million Bet On New Leukemia Drugs\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-01-08 02:45 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/m-a/26/01/49764675/amgen-buys-dark-blue-in-840-million-bet-on-new-leukemia-drugs><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>On Tuesday, Amgen Inc. (NASDAQ:AMGN) acquired Dark Blue Therapeutics, a discovery and development biotech company focused on precision oncology medicines.\nThe acquisition values Dark Blue Therapeutics...</p>\n\n<a href=\"https://www.benzinga.com/m-a/26/01/49764675/amgen-buys-dark-blue-in-840-million-bet-on-new-leukemia-drugs\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0058720904.USD","symbol_name":"联博国际健康护理基金A","start_time":0,"source_url":"https://www.benzinga.com/m-a/26/01/49764675/amgen-buys-dark-blue-in-840-million-bet-on-new-leukemia-drugs","article_id":"2601383721","we_media_id":null,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/01/07/Amgen-Photo-by-JHVEPhoto-via-Shutterstoc.jpeg?optimize=medium&dpr=2&auto=webp&width=630"],"rights":{"source":"benzinga_hot_news","url":"https://www.benzinga.com/m-a/26/01/49764675/amgen-buys-dark-blue-in-840-million-bet-on-new-leukemia-drugs","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2601383721","pubTimestamp":1767811500,"columns":[],"sourceInfo":{"source_id":"benzinga_hot_news","name":"Benzinga"},"weMediaInfo":null,"summary":"On Tuesday, Amgen Inc.  acquired Dark Blue Therapeutics, a discovery and development biotech company focused on precision oncology medicines.The acquisition values Dark Blue Therapeutics at up to $840 million, including upfront and future milestones.Dark Blue’s lead candidate, DBT 3757, is currently in IND-enabling studies for acute myeloid leukemia  and acute lymphoblastic leukemia .Leukemia is a cancer of the blood-forming tissues, like bone marrow, causing rapid production of abnormal white blood cells that crowd out healthy cells.Amgen expects to integrate Dark Blue Therapeutics into its existing research organization, further strengthening the company’s early oncology discovery efforts.AMGN Price Action: Amgen shares were up 2.89% at $339.71 at the time of publication on Wednesday. The stock is approaching its 52-week high of $346.38, according to Benzinga Pro data.","collect":0,"end_time":0,"defaultTopTitle":"benzinga.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0058720904.USD":"联博国际健康护理基金A","LU1074936037.SGD":"JPMorgan Funds - US Value A (acc) SGD","LU2242646821.SGD":"Fidelity Global Dividend Plus A-MINCOME(G)-SGD","BK4559":"巴菲特持仓","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","LU1670710588.SGD":"M&G (LUX) GLOBAL DIVIDEND \"A\" (SGD) ACC","LU2355687059.USD":"NORDEA 1 GLOBAL IMPACT  \"BP\" (USD) ACC","BK4566":"资本集团","BK4588":"碎股","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU0237698245.USD":"富达环球地产基金A","LU1430594728.SGD":"Eastspring Investments - Global Low Volatility Equity AS SGD","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","LU1571399168.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"IP\" (USD) ACC","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","BMY":"施贵宝","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","LU1670710661.SGD":"M&G (LUX) GLOBAL DIVIDEND \"A\" (SGD) INC","ALL":"好事达","BK4007":"制药","IE00BFXG1179.USD":"BNY MELLON U.S. EQUITY INCOME \"B\" (USD) INC","LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","LU0306806265.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" ACC","LU1718418525.SGD":"JPMorgan Investment Funds - Global Select Equity A (acc) SGD","BK4581":"高盛持仓","BK4532":"文艺复兴科技持仓","LU0225771236.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (USD) INC MF","LU1323610961.USD":"UBS (LUX) EQUITY SICAV - LONG TERM THEMES (USD) \"P\" (USD) ACC","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","LU2360032135.SGD":"ALLSPRING GLOBAL EQUITY ENHANCED INCOME \"A\" (SGDHDG) INC","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","LU2133065610.SGD":"JPMorgan Investment Funds - Global Dividend A (mth) SGD","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","LU1868836757.USD":"CT (LUX) I AMERICAN FUND \"2\" (USD) ACC","BK4585":"ETF&股票定投概念","AMGN":"安进","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","LU1032466523.USD":"高盛全球多资产收益组合Acc","LU0882574055.USD":"富达全球健康医疗A ACC","LU1670711040.USD":"M&G (LUX) GLOBAL DIVIDEND \"A\" (USD) ACC","EVO":"Evotec SE","LU0096364046.USD":"CT (LUX) I AMERICAN \"DU\" (USD) ACC","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","LU0267386448.USD":"FIDELITY FIRST ALL COUNTRY WORLD \"A\" (USD) INC","LU1261432733.SGD":"Fidelity World A-ACC-SGD","LU1983299246.USD":"SCHRODER ISF HEALTHCARE INNOVATION \"A\" (USD) ACC","LU0321505868.SGD":"Schroder ISF Global Dividend Maximiser A Dis SGD","LU1989771016.USD":"东方汇理环球老龄化投资基金 A2 Acc"},"translate_title":"安进以8.4亿美元收购Dark Blue，押注白血病新药","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BMY":1,"AMGN":1.5,"EVO":1,"ALL":1},"content_text":"On Tuesday, Amgen Inc. (NASDAQ:AMGN) acquired Dark Blue Therapeutics, a discovery and development biotech company focused on precision oncology medicines.\nThe acquisition values Dark Blue Therapeutics at up to $840 million, including upfront and future milestones.\nDark Blue’s lead candidate, DBT 3757, is currently in IND-enabling studies for acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).\nLeukemia is a cancer of the blood-forming tissues, like bone marrow, causing rapid production of abnormal white blood cells that crowd out healthy cells.\nDark Blue has been strongly supported by investors Oxford Science Enterprises, Bristol Myers Squibb Co (NYSE:BMY), and Evotec SE (NASDAQ:EVO).\nAmgen expects to integrate Dark Blue Therapeutics into its existing research organization, further strengthening the company’s early oncology discovery efforts.\n“This acquisition complements and extends our research in targeted protein degradation and leukemia therapeutics, advancing our strategy to invest early in rising medicines for novel therapeutic targets. The adjacency of this program to our considered expertise in cancer biology will propel MLLT1/3-targeting medicines to clinical investigation for patients facing the challenging diagnosis of AML,” said Jay Bradner, executive vice president of Research and Development at Amgen.\nIn December 2025, the U.S. Food and Drug Administration approved Amgen’s Uplinza (inebilizumab-cdon) for generalized myasthenia gravis.\nAMGN Price Action: Amgen shares were up 2.89% at $339.71 at the time of publication on Wednesday. The stock is approaching its 52-week high of $346.38, according to Benzinga Pro data.\nPhoto by JHVEPhoto via Shutterstock","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"corporation,productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2601383721","isCrawlerRequest":true}